Neuren Pharmaceuticals Limited · ASX:NEU
Neuren Pharmaceuticals — Investor Presentation (February 2017)
23 slides from Neuren Pharmaceuticals's investor presentation, Feb 2, 2017
Slide 1: Investor Presentation
For personal use only Investor Presentation 2 February 2017 1
Slide 2: Forward looking statements
Forward looking statements For personal use only This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Neuren can give no assurance that these expe
Slide 3: Neuren snapshot
Neuren snapshot For personal use only Stock code ASX: NEU – market cap approximately A$130 million Developing new treatments for neurological conditions Significant unmet needs and commercial opportunities with no approved drugs Regulatory advantages – candidates for Fast Track, Orphan Drug,
Slide 4: Scientific foundation
Scientific foundation For personal use only IGF-1 is a naturally occurring growth factor in the brain Glypromate (GPE) separates from IGF-1 in the brain IGF-1 and GPE maintain and restore equilibrium in the brain Trofinetide is a synthetic analogue of GPE with a longer half-life, better stab
Slide 5: Multiple disorders with common causes and effects
Multiple disorders with common causes and effects Neuro- Microglial Neuronal Apoptosis Impaired Oxidative inflammation Activation signaling Neurogenesis stress Rett ▪ ▪ ▪ ▪ ▪ ▪ For personal use only Fragile X ▪ ▪ ▪ ▪ ▪ Traumatic brain injury ▪ ▪ ▪ ▪ ▪ ▪ Idiopathic autism Cognitive impairment Depress
Slide 6: Trofinetide development strategy
Trofinetide development strategy For personal use only Common foundation: Acute and chronic toxicity studies Commercial manufacturing Phase 1 clinical studies Neurodevelopmental Neurodegenerative Acute brain injury disorders diseases Rett syndrome: Severe and moderate TBI: Phase 2 trial completed Pa
Slide 7: Trofinetide commercial exclusivity
Trofinetide commercial exclusivity For personal use only Issued composition of matter patents owned by Neuren US and Europe – expire 2022, potential to extend to 2027 Exclusivity periods from orphan drug designation in Rett syndrome and Fragile X syndrome US – 7 years from marketing authoriz
Slide 8: Trofinetide in Rett syndrome
Trofinetide in Rett syndrome For personal use only Non-inherited mutation on the X chromosome – estimated 1/10,000 females Most physically disabling of the autism spectrum disorders - symptoms include: Intellectual disability, loss of speech and motor control Compulsive hand movements Diso
Slide 9: Completed Phase 2 trial in adults and adolescents
Completed Phase 2 trial in adults and adolescents For personal use only Double-blind, placebo-controlled Phase 2 trial of 28 days of treatment with two dose levels (35 mg/kg and 70 mg/kg of body weight twice daily) 56 subjects aged 16 to 45 years randomized, with 53 subjects completing the trial
Slide 10: Core efficacy measures that met target
Core efficacy measures that met target For personal use only Motor Behavior Assessment Change Index Clinical Global Impression of Improvement Absolute value Caregiver Top 3 Concerns Analysis of group mean values Solid line is 70mg/kg, dotted line is placebo The two different shaded areas indic
Slide 11: Subject-level efficacy analysis
Subject-level efficacy analysis For personal use only Solid line is 70mg/kg, dotted line is Mean subject-level efficacy score placebo The two different shaded areas indicate the treatment period and the period post-cessation of treatment A positive value on the y-axis indicates clinical improv
Slide 12: Motor Behavior Assessment (MBA)
Motor Behavior Assessment (MBA) For personal use only No precedent for efficacy measures in Rett syndrome clinical trials for registration Motor Behavior Assessment (MBA) is a clinician completed instrument to measure the core signs and symptoms of Rett syndrome Used to assess over 1,100 child
Slide 13: Current Phase 2 trial in girls aged 5 to 15
Current Phase 2 trial in girls aged 5 to 15 For personal use only Double-blind, placebo-controlled Phase 2 trial in subjects aged 5 to 15 years Evaluate safety and efficacy of higher doses in younger population with longer treatment To confirm optimum dose levels for subsequent Phase 3 trial i
Slide 14: Trofinetide in Fragile X syndrome
Trofinetide in Fragile X syndrome For personal use only Inherited X chromosome mutation – full mutation causes Fragile X syndrome 1 / 4,000 males and 1 / 6,000 females estimated to have full mutation More severe in males, ~50% of females have some features of the syndrome The most common inh
Slide 15: Completed Phase 2 trial in adolescents and adults
Completed Phase 2 trial in adolescents and adults For personal use only Double-blind, placebo-controlled Phase 2 trial of 28 days of treatment with two dose levels (35 mg/kg and 70 mg/kg of body weight twice daily) 70 subjects aged 12 to 45 years received treatment, with 68 subjects completing t
Slide 16: Core efficacy measures that met target
Core efficacy measures that met target For personal use only Fragile X Syndrome Rating Scale Fragile X Domain Specific Concerns Aberrant Behavior Checklist (ABC) Total Score Analysis of mean clinical responses at end of treatment for each treatment group A negative value on the y-axis indicates
Slide 17: Subject-level efficacy analysis
Subject-level efficacy analysis For personal use only Mean of individual subject scorecards A positive value on the y-axis indicates clinical improvement Changes in all 5 core efficacy measures at end of treatment were combined in an efficacy score for each subject Mean efficacy scores were th
Slide 18: Trofinetide in Traumatic Brain Injury (TBI)
Trofinetide in Traumatic Brain Injury (TBI) For personal use only >1.5 million head injuries annually in the US alone Leading cause of death and disability, especially in young and elderly No approved treatments available Partnership funding of ~US$25 million has been contributed by US Army
Slide 19: Next steps in TBI
Next steps in TBI For personal use only Neuren and US Army discussing feasibility of a second trial in severe TBI, or moderate to severe TBI, optimised by including: RBANS as primary efficacy endpoint More targeted definition of trial population Randomisation stratified by injury severity
Slide 20: Other development activities for trofinetide
Other development activities for trofinetide For personal use only Manufacturing process required for pivotal trials, New Drug Application (NDA) and commercial supply Optimization and scale-up of API synthesis and isolation continuing To-be-marketed drug product stability testing in progress
Slide 21: Second drug candidate: NNZ-2591
Second drug candidate: NNZ-2591 For personal use only Cyclic dipeptide with higher oral bioavailability, improved stability and potential for oral solid dosage form Demonstrated efficacy in pre-clinical models of Parkinson’s disease, stroke, traumatic brain injury, peripheral neuropathy, Fragile
Slide 22: Share information
Share information For personal use only Issued shares: 1.84 billion1 Closing price 31 January 2017: 7.3 cents 52 week range: 4.1 cents – 13.0 cents 1 Includes 90 million loan funded shares, which will provide additional funds of $6 million when loans are repaid. 8% 11% Retail 62% Langley Walker rele
Slide 23: Key milestones
Key milestones For personal use only Milestone Estimated timing Top-line results from Rett syndrome pediatric Phase 2 trial March 2017 Complete chronic toxicity studies for NDA’s and Phase 3 trials: • First species H1 2017 • Second species H1 2018 Initiate manufacturing for Rett syndrome Phase 3 tri
Neuren Pharmaceuticals — Investor Presentation (February 2017) on 6ix